Conceptio › Archive › Google Patents

Google Patentsopen access

Engineering and optimization of improved systems, methods and enzyme … — The Broad Institute, Inc. (US20250236856A1)

The Broad Institute, Inc. · Google Patents

Google Patents · Patents · License: Open Access

Open Source ↗

fengzhang thebroadinstitute

patent, google patents, intellectual property, US20250236856A1, The Broad Institute, Inc., Feng Zhang, en, 2025

ABSTRACT

Abstract

The invention provides for engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are compositions and methods related to components of a CRISPR complex particularly comprising a Cas ortholog enzyme.

Description

RELATED APPLICATIONS AND INCORPORATION BY REFERENCE

This application is a continuation of U.S. patent application Ser. No. 15/330,875, filed Nov. 7, 2016, which is a continuation of U.S. patent application Ser. No. 14/104,977, filed Dec. 12, 2013, which claims priority to U.S. provisional patent application 61/836,101 entitled ENGINEERING AND OPTIMIZATION OF IMPROVED SYSTEMS, METHODS AND ENZYME COMPOSITIONS FOR SEQUENCE MANIPULATION filed on Jun. 17, 2013. This application also claims priority to U.S. provisional patent applications 61/758,468; 61/769,046; 61/802,174; 61/806,375; 61/814,263; 61/819,803 and 61/828,130 each entitled ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION, filed on Jan. 30, 2013; Feb. 25, 2013; Mar. 15, 2013; Mar. 28, 2013; Apr. 20, 2013; May 6, 2013 and May 28, 2013, respectively. This application also claims priority to U.S. provisional patent applications 61/736,527 and 61/748,427, both entitled SYSTEMS METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION filed on Dec. 12, 2012 and Jan. 2, 2013, respectively. Priority is also claimed to U.S. provisional patent applications 61/791,409 and 61/835,931 filed on Mar. 15, 2013 and Jun. 17, 2013 respectively.

Reference is also made to U.S. provisional patent applications 61/836,127, 61/835,936, 61/836,080, 61/836,123, and 61/835,973 each filed Jun. 17, 2013.

The foregoing applications, and all documents cited therein or during their prosecution (âappln cited documentsâ) and all documents cited or referenced in the appln cited documents, and all documents cited or referenced herein (âherein cited documentsâ), and all documents cited or referenced in herein cited documents, together with any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention. More specifically, all referenced documents are incorporated by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference.

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

This invention was made with government support under Grant No. MH100706 awarded by the National Institutes of Health. The government has certain rights in the invention.

FIELD OF THE INVENTION

The present invention generally relates to the engineering and optimization of systems, methods and compositions used for the control of gene expression involving sequence targeting, such as genome perturbation or gene-editing, that relate to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and components thereof.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on Apr. 13, 2025, is named 114203-6215_SL.xml and is 401,275 bytes in size.

BACKGROUND OF THE INVENTION

Recent advances in genome sequencing techniques and analysis methods have significantly accelerated the ability to catalog and map genetic factors associated with a diverse range of biological functions and diseases. Precise genome targeting technologies are needed to enable systematic reverse engineering of causal genetic variations by allowing selective perturbation of individual genetic elements, as well as to advance synthetic biology, biotechnological, and medical applications. Although genome-editing techniques such as designer zinc fingers, transcription activator-like effectors (TALEs), or homing meganucleases are available for producing targeted genome perturbations, there remains a need for new genome engineering technologies that are affordable, easy to set up, scalable, and amenable to targeting multiple positions within the eukaryotic genome.

SUMMARY OF THE INVENTION

The CRISPR/Cas or the CRISPR-Cas system (both terms are used interchangeably throughout this application) does not require the generation of customized proteins to target specific sequences but rather a single Cas enzyme can be programmed by a short RNA molecule to recognize a specific DNA target, in other words the Cas enzyme can be recruited to a specific DNA target using said short RNA molecule. Adding the CRISPR-Cas system to the repertoire of genome sequencing techniques and analysis methods may significantly simplify the methodology and accelerate the ability to catalog and map genetic factors associated with a diverse range of biological functions and diseases. To utilize the CRISPR-Cas system effectively for genome editing without deleterious effects, it is critical to understand aspects of engineering and optimization of these genome engineering tools, which are aspects of the claimed invention.

Accordingly, there exists a pressing need for alternative and robust systems and techniques for sequence targeting with a wide array of applications. Aspects of this invention address this need and provide related advantages. An exemplary CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within the target polynucleotide, wherein the CRISPR enzyme is a Cas ortholog, e.g. a Cas9 ortholog, of a genus which includes but is not limited to Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma and Campylobacter . The guide sequence is linked to a tracr mate sequence, which in turn hybridizes to a tracr sequence.

In one aspect, the invention provides methods for using one or more elements of a CRISPR system. The CRISPR complex of the invention provides an effective means for modifying a target polynucleotide. The CRISPR complex of the invention has a wide variety of utilities including modifying (e.g., deleting, inserting, translocating, inactivating, activating, repressing, altering methylation, transferring specific moieties) a target polynucleotide in a multiplicity of cell types. As such the CRISPR complex of the invention has a broad spectrum of applications in, e.g., gene or genome editing, gene regulation, gene therapy, drug discovery, drug screening, disease diagnosis, and prognosis. In preferred aspects of the invention, the CRISPR complex comprises a Cas enzyme, preferably a Cas9 ortholog, of a genus which includes but is not limited to Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma and Campylobacter.

Aspects of the invention relate to CRISPR enzymes having optimized function. With regard to the CRISPR enzyme being a Cas enzyme, preferred embodiments of the invention relate to Cas9 orthologs having improved target specificity in a CRISPR-Cas9 system. This may be accomplished by approaches that include but are not limited to designing and preparing guide RNAs having optimal activity, selecting Cas9 enzymes of a specific length, truncating the Cas9 enzyme making it smaller in length than the corresponding wild-type Cas9 enzyme by truncating the nucleic acid molecules coding therefor and generating chimeric Cas9 enzymes wherein different parts of the enzyme are swapped or exchanged between different orthologs to arrive at chimeric enzymes having tailored specificity. Aspects of the invention also relate to methods of improving the target specificity of a Cas9 ortholog enzyme or of designing a CRISPR-Cas9 system comprising designing or preparing guide RNAs having optimal activity and/or selecting or preparing a Cas9 ortholog enzyme having a smaller size or length than the corresponding wild-type Cas9 whereby packaging a nucleic acid coding therefor into a delivery vector is advanced as there is less coding sequence therefor in the delivery vector than for the corresponding wild-type Cas9 and/or generating chimeric Cas9 enzymes.

Also provided are uses of the present sequences, vectors, enzymes or systems, in medicine. Also provided are the same for use in gene or genome editing. Also provided is use of the same in the manufacture of a medicament for gene or genome editing, for instance treatment by gene or genome editing. Also provided are the present sequences, vectors, enzymes or systems for use in therapy.

In an additional aspect of the invention, a CRISPR enzyme, e.g. a Cas9 enzyme may comprise one or more mutations and may be used as a generic DNA binding protein with or without fusion to or being operably linked to a functional domain. The mutations may be artificially introduced mutations and may include but are not limited to one or more mutations in a catalytic domain. Examples of catalytic domains with reference to a Cas9 enzyme may include but are not limited to RuvC I, RuvC II, RuvC III and HNH domains. Preferred examples of suitable mutations are the catalytic residue(s) in the N-term RuvC I domain of Cas9 or the catalytic residue(s) in the internal HNH domain. In some embodiments, the Cas9 is (or is derived from) the Streptococcus pyogenes Cas9 (SpCas9). In such embodiments, preferred mutations are at any or all of positions 10, 762, 840, 854, 863 and/or 986 of SpCas9 or corresponding positions in other Cas9 orthologs with reference to the position numbering of SpCas9 (which may be ascertained for instance by standard sequence comparison tools, e.g. ClustalW or MegAlign by Lasergene 10 suite). In particular, any or all of the following mutations are preferred in SpCas9: D10A, E762A, H840A, N854A, N863A and/or D986A; as well as conservative substitution for any of the replacement amino acids is also envisaged. The same mutations (or conservative substitutions of these mutations) at corresponding positions with reference to the position numbering of SpCas9 in other Cas9 orthologs are also preferred. Particularly preferred are D10 and H840 in SpCas9. However, in other Cas9s, residues corresponding to SpCas9 D10 and H840 are also preferred. These are advantageous as when singly mutated they provide nickase activity and when both mutations are present the Cas9 is converted into a catalytically null mutant which is useful for generic DNA binding. Further mutations have been identified and characterized. Other aspects of the invention relate to the mutated Cas 9 enzyme being fused to or operably linked to domains which include but are not limited to a transcriptional activator, transcriptional repressor, a recombinase, a transposase, a histone remodeler, a DNA methyltransferase, a cryptochrome, a light inducible/controllable domain or a chemically inducible/controllable domain.

A further aspect of the invention provides for chimeric Cas9 proteins and methods of generating chimeric Cas9 proteins. Chimeric Cas9 proteins are proteins that comprise fragments that originate from different Cas9 orthologs. For instance, the N-terminal of a first Cas9 ortholog may be fused with the C-terminal of a second Cas9 ortholog to generate a resultant Cas9 chimeric protein. These chimeric Cas9 proteins may have a higher specificity or a higher efficiency than the original specificity or efficiency of either of the individual Cas9 enzymes from which the chimeric protein was generated. These chimeric proteins may also comprise one or more mutations or may be linked to one or more functional domains. Therefore, aspects of the invention relate to a chimeric Cas enzyme wherein the enzyme comprises one or more fragments from a first Cas ortholog and one or more fragments from a second Cas ortholog. In a embodiment of the invention the one or more fragments of the first or second Cas ortholog are from the C- or N-terminal of the first or second Cas ortholog. In a further embodiment the first or second Cas ortholog is selected from a genus belonging to the group consisting of Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma and Campylobacter.

In a further embodiment, the invention provides for methods to generate mutant components of the CRISPR complex comprising a Cas enzyme, e.g Cas9 ortholog. The mutant components may include but are not limited to mutant tracrRNA and tracr mate sequences or mutant chimeric guide sequences that allow for enhancing performance of these RNAs in cells. Use of the present composition or the enzyme in the preparation of a medicament for modification of a target sequence is also provided.

The invention in yet a further aspect provides compositions and methods related to a non-naturally occurring or engineered composition comprising:

A)âI. a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises: (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, (b) a tracr mate sequence, and (c) a tracr sequence, and II. a polynucleotide sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences, wherein (a), (b) and (c) are arranged in a 5â² to 3â² orientation, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence and the polynucleotide sequence encoding a CRISPR enzyme is DNA or RNA, or (B) I. polynucleotides comprising: (a) a guide sequence capable of hybridizing to a target sequence in a prokaryotic cell, and (b) at least one or more tracr mate sequences, II. a polynucleotide sequence encoding a CRISPR enzyme, and III. a polynucleotide sequence comprising a tracr sequence, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, and the polynucleotide sequence encoding a CRISPR enzyme is DNA or RNA, and wherein the CRISPR enzyme is a Cas9 ortholog of a genus belonging to the group consisting of Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma and Campylobacter.

RELATED APPLICATIONS AND INCORPORATION BY REFERENCE

Reference is also made to U.S. provisional patent applications 61/836,127, 61/835,936, 61/836,080, 61/836,123, and 61/835,973 each filed Jun. 17, 2013.

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

This invention was made with government support under Grant No. MH100706 awarded by the National Institutes of Health. The government has certain rights in the invention.

FIELD OF THE INVENTION

SEQUENCE LISTING

BACKGROUND OF THE INVENTION

SUMMARY OF THE INVENTION

The invention in yet a further aspect provides compositions and methods related to a non-naturally occurring or engineered composition comprising:

The invention in yet a further aspect provides: (A) A non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising: I. a first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, (b) a tracr mate sequence, and (c) a tracr sequence, and II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences, wherein (a), (b) and (c) are arranged in a 5â² to 3â² orientation, wherein components I and II are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, wherein the CRISPR enzyme is a Cas9 ortholog of a genus belonging to the group consisting of Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma and Campylobacter or (B) a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising I. a first regulatory element operably linked to (a) a guide sequence capable of hybridizing to a target sequence in a prokaryotic cell, and (b) at least one or more tracr mate sequences, II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme, and III. a third regulatory element operably linked to a tracr sequence, wherein components I, II and III are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, wherein the CRISPR enzyme is a Cas9 ortholog of a genus belonging to the group consisting of Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma and Campylobacter , and wherein: at least one of the following criteria applies.

The criteria are as follows and it will be appreciated that any number of these may apply, preferably 1 or more, preferably 2 or more, and preferably 3 or more, 4 or more, or 5 or more, or all may apply:

the CRISPR enzyme having a specific size is selected and has a length of at least 500 amino acids, at least 800-899 amino acids, at least 900-999 amino acids, at least 1000-1099 amino acids, at least 1100-1199 amino acids, at least 1200-1299 amino acids, at least 1300-1399 amino acids, at least 1400-1499 amino acids, at least 1500-1599 amino acids, at least 1600-1699 amino acids or at least 2000 amino acids; and/or the CRISPR enzyme is truncated in comparison to the corresponding wild type CRISPR enzyme; and/or the CRISPR enzyme is a nuclease directing cleavage of both strands at the location of the target sequence, or the CRISPR enzyme is a nickase directing cleavage of one strand at the location of the target sequence; and/or the guide sequence comprises at least 10, at least 15 or at least 20 nucleotides; and/or the CRISPR enzyme is codon-optimized or codon-optimized for expression in a eukaryotic cell; and/or the CRISPR enzyme comprises one or more mutations; and/or the CRISPR enzyme comprises a chimeric CRISPR enzyme; and/or the CRISPR enzyme has one or more other attributes herein discussed.

In some embodiments, the CRISPR enzyme is truncated in comparison to a wild type CRISPR enzyme or the CRISPR enzyme is comprised of at least 500 amino acids, at least 800-899 amino acids, at least 900-999 amino acids, at least 1000-1099 amino acids, at least 1100-1199 amino acids, at least 1200-1299 amino acids, at least 1300-1399 amino acids, at least 1400-1499 amino acids, at least 1500-1599 amino acids, at least 1600-1699 amino acids or at least 2000 amino acids. In preferred embodiments the CRISPR enzyme is a Cas enzyme, e.g. a Cas9 ortholog.

In some embodiments, the CRISPR enzyme is a nuclease directing cleavage of both strands at the location of the target sequence, or the CRISPR enzyme is a nickase directing cleavage of one strand at the location of the target sequence. In further embodiments, the CRISPR enzyme is a catalytically null mutant that is a generic DNA binding protein. In preferred embodiments the CRISPR enzyme is a Cas enzyme, e.g. a Cas9 ortholog.

In some embodiments, the guide sequence comprises at least fifteen nucleotides. In some embodiments, the CRISPR enzyme is codon-optimized or codon-optimized for expression in a eukaryotic cell. In some embodiments, the CRISPR enzyme comprises one or more mutations. In some embodiments, the CRISPR enzyme comprises a chimeric CRISPR enzyme. In some embodiments, the CRISPR enzyme has one or more other attributes herein discussed. In preferred embodiments the CRISPR enzyme is a Cas enzyme, e.g. a Cas9 ortholog.

In certain embodiments, the CRISPR enzyme comprises one or more mutations. The one or more mutations may be in a particular domain of the enzyme. In a preferred embodiment, the one or more mutations may be in a catalytic domain. In a further preferred embodiment the catalytic domain is a RuvC I, RuvC II, RuvC III or HNH domain. In a more preferred embodiment, the one or more mutations is in a RuvC1 or HNH domain of the CRISPR enzyme. In a further preferred embodiment the CRISPR enzyme is a Cas enzyme, e.g. a Cas9 ortholog and the mutation may be at one or positions that include but are not limited to positions that correspond to D10A, E762A, H840A, N854A, N863A or D986A with reference to the position numbering of SpCas9 and/or is a mutation as otherwise discussed herein. In some embodiments, the CRISPR enzyme has one or more mutations in a particular domain of the enzyme, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the enzyme further comprises a functional domain. The functional domain may include but is not limited to transcriptional activator, transcriptional repressor, a recombinase, a transposase, a histone remodeler, a DNA methyltransferase, a cryptochrome, a light inducible/controllable domain or a chemically inducible/controllable domain.

In some embodiments, the functional domain is the transcriptional activator domain VP64. In some embodiments, the functional domain is the transcriptional repressor domain KRAB. In some embodiments, the transcriptional repressor domain is SID, or concatemers of SID (i.e. SID4X). In some embodiments, an epigenetic modifying enzyme is provided, e.g a histone modifying protein or an epigenetic chromatin modifying protein. In some embodiments, an activator domain is provided, which may be the P65 activator domain.

A further aspect of the invention comprehends methods of modifying two or more genomic loci of interest. In a preferred embodiment of the invention two or more genomic loci are differentially modulated by utilizing one or more CRISPR enzymes, e.g. two or more Cas9 orthologs, each ortholog being operably linked to one or more functional domain. In one aspect, the invention provides for a method of modifying two or more genomic loci in a eukaryotic cell. Therefore, aspects of the invention provide for a method of modulating the expression of two or more genomic loci of interest in an organism comprising delivering a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising

I. a first regulatory element operably linked to a first CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the first polynucleotide sequence comprises

(i) a first guide sequence capable of hybridizing to a first target sequence at a first genomic locus in a cell of the organism, (ii) a first tracr mate sequence, and (iii) a first tracr sequence, and II. a second regulatory element operably linked to a second CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the second polynucleotide sequence comprises (i) a second guide sequence capable of hybridizing to a second target sequence at a second genomic locus in the cell of the organism, (ii) a second tracr mate sequence, and (iii) a second tracr sequence, and III. a third regulatory element operably linked to an enzyme-coding sequence encoding a first CRISPR enzyme comprising at least one or more nuclear localization sequences and operably linked to a first functional domain, IV. a fourth regulatory element operably linked to an enzyme-coding sequence encoding a second CRISPR enzyme comprising at least one or more nuclear localization sequences and operably linked to a second functional domain, wherein (i), (ii) and (iii) in I and II are arranged in a 5â² to 3â² orientation, wherein components I, II, III and IV are located on the same or different vectors of the system, wherein when transcribed, each tracr mate sequences hybridizes to its corresponding tracr sequence and the first and second guide sequences direct sequence-specific binding of the first and second CRISPR complex to the first and second target sequence, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence and wherein expression of the CRISPR enzyme provides manipulation of the target sequence, wherein the first and second CRISPR enzyme each comprise two or more mutations, wherein the first and second CRISPR enzyme is a Cas9 ortholog of a genus belonging to the group consisting of Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma and Campylobacter , and wherein the first genomic locus is modulated by the activity of the first functional domain and the second genomic locus is modulated by the activity of the second functional domain. In a further embodiment the first functional domain is selected from the group consisting of a transcriptional activator, transcriptional repressor, a recombinase, a transposase, a histone remodeler, a DNA methyltransferase, a cryptochrome and a light inducible/controllable domain or a chemically inducible/controllable domain. In a further embodiment the second functional domain is selected from the group consisting of a transcriptional activator, transcriptional repressor, a recombinase, a transposase, a histone remodeler, a DNA methyltransferase, a cryptochrome and a light inducible/controllable domain or a chemically inducible/controllable domain. In preferred embodiments the first or second CRISPR enzyme is a Sutterella wadsworthensis Cas9, a Filifactor alocis Cas9, a Lactobacillus johnsonii Cas9, a Campylobacter lari Cas9, a Corynebacter diptheriae Cas9, a Parvibaculum lavamentivorans Cas9, a Mycoplasma gallisepticum Cas9, a Staphylococcus aureus subsubspecies Aureus Cas9, a Legionella pneumophila Paris Cas9, a Treponema denticola Cas9, a Staphylococcus pseudintermedius Cas9, a Neisseria cinerea Cas9.

In some embodiments, the CRISPR enzyme is a type I, II or III CRISPR enzyme, preferably a type II CRISPR enzyme. This type II CRISPR enzyme may be any Cas enzyme. A Cas enzyme may be identified as Cas9 as this can refer to the general class of enzymes that share homology to the biggest nuclease with multiple nuclease domains from the type II CRISPR system. Most preferably, the Cas9 enzyme is from, or is derived from, SpCas9 or Staphylococcus aureus subsubspecies Aureus SaCas9. By derived, it is meant that the derived enzyme is largely based, in the sense of having a high degree of sequence homology with, a wildtype enzyme, but that it has been mutated (modified) in some way as described herein.

It will be appreciated that the terms Cas and CRISPR enzyme are generally used herein interchangeably, unless otherwise apparent. As mentioned above, many of the residue numberings used herein refer to the Cas9 enzyme from the type II CRISPR locus in Streptotoccus pyogenes . However, it will be appreciated that this invention includes many more Cas9s from other species of microbes such as those belonging to the genus Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma or Campylobacter , such as SpCas9, SaCas9, St1Cas9, St3Cas9 and so forth, wherein St is Streptococcus thermophilus.

An example of a codon optimized sequence, in this instance optimized for humans (i.e. being optimized for expression in humans) is provided herein, see the SaCas9 human codon optimized sequence. Whilst this is preferred, it will be appreciated that other examples are possible and codon optimization for a host species is known.

Further aspects of the invention relate to improved cleavage specificity, optimized tracr sequence, optimized chimeric guide RNA, co-fold structure of tracrRNA and tracr mate sequence, stabilizing secondary structures of tracr RNA, tracrRNA with shortened region of base pairing, tracrRNA with fused RNA elements, simplified cloning and delivery, reduced toxicity and/or inducible systems. Another aspect of the invention relates to the stabilization of chimeric RNA, and/or guide sequence and or a portion thereof of CRISPR complexes wherein the CRISPR enzyme is a CRISPR ortholog, wherein the chimeric RNA, and/or guide sequence and or a portion thereof is stabilized by synthetic or chemically modified nucleotides (e.g. LNA/BNA: thiol-modification, 2â²/3â²-OH crosslink modification), is modified to be degradation/hydrolysis resistant and to which elements of structural stability have been added.

The invention further comprehends in certain embodiments a method of modifying an organism or a non-human organism by manipulation of a target sequence in a genomic locus of interest comprising delivering a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors operably encoding a composition herein discussed for expression thereof. Preferably, the vector is a viral vector, such as a lenti- or baculo- or preferably adeno-viral/adeno-associated viral vectors, but other means of delivery are known (such as yeast systems, microvesicles, gene guns/means of attaching vectors to gold nanoparticles) and are provided.

Various means of delivery are described herein, and further discussed in this section.

Viral delivery: The CRISPR enzyme, for instance a Cas9, and/or any of the present RNAs, for instance a guide RNA, can be delivered using adeno associated virus (AAV), lentivirus, adenovirus or other viral vector types, or combinations thereof. Cas9 and one or more guide RNAs can be packaged into one or more viral vectors. In some embodiments, the viral vector is delivered to the tissue of interest by, for example, an intramuscular injection, while othertimes the viral delivery is via intravenous, transdermal, intranasal, oral, mucosal, or other delivery methods. Such delivery may be either via a single dose, or multiple doses. One skilled in the art understands that the actual dosage to be delivered herein may vary greatly depending upon a variety of factors, such as the vector chosen, the target cell, organism, or tissue, the general condition of the subject to be treated, the degree of transformation/modification sought, the administration route, the administration mode, the type of transformation/modification sought, etc.

Such a dosage may further contain, for example, a carrier (water, saline, ethanol, glycerol, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, etc.), a diluent, a pharmaceutically-acceptable carrier (e.g., phosphate-buffered saline), a pharmaceutically-acceptable excipient, an adjuvant enhance antigenicity, an immunostimulatory compound or molecule, and/or other compounds known in the art. The adjuvant herein may contain a suspension of minerals (alum, aluminum hydroxide, aluminum phosphate) on which antigen is adsorbed; or water-in-oil emulsion in which antigen solution is emulsified in oil (MF-59, Freund's incomplete adjuvant), sometimes with the inclusion of killed mycobacteria (Freund's complete adjuvant) to further enhance antigenicity (inhibits degradation of antigen and/or causes influx of macrophages). Adjuvants also include immunostimulatory molecules, such as cytokines, costimulatory molecules, and for example, immunostimulatory DNA or RNA molecules, such as CpG oligonucleotides. Such a dosage formulation is readily ascertainable by one skilled in the art. The dosage may further contain one or more pharmaceutically acceptable salts such as, for example, a mineral acid salt such as a hydrochloride, a hydrobromide, a phosphate, a sulfate, etc.; and the salts of organic acids such as acetates, propionates, malonates, benzoates, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, gels or gelling materials, flavorings, colorants, microspheres, polymers, suspension agents, etc. may also be present. In addition, one or more other conventional pharmaceutical ingredients, such as preservatives, humectants, suspending agents, surfactants, antioxidants, anticaking agents, fillers, chelating agents, coating agents, chemical stabilizers, etc. may also be present, especially if the dosage form is a reconstitutable form. Suitable exemplary ingredients include microcrystalline cellulose, carboxymethylcellulose sodium, polysorbate 80, phenylethyl alcohol, chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, the parabens, ethyl vanillin, glycerin, phenol, parachlorophenol, gelatin, albumin and a combination thereof. A thorough discussion of pharmaceutically acceptable excipients is available in REMINGTON'S PHARMACEUTICAL SCIENCES (Mack Pub. Co., N.J. 1991) which is incorporated by reference herein.

In an embodiment herein the delivery is via an adenovirus, which may be at a single booster dose containing at least 1Ã10 5 particles (also referred to as particle units, pu) of adenoviral vector. In an embodiment herein, the dose preferably is at least about 1Ã10 6 particles (for example, about 1Ã10 6 -1Ã10 12 particles), more preferably at least about 1Ã10 7 particles, more preferably at least about 1Ã10 8 particles (e.g., about 1Ã10 8 -1Ã10 11 particles or about 1Ã10 8 -1Ã10 12 particles), and most preferably at least about 1Ã10 0 particles (e.g., about 1*Ã 10 9 -1Ã10 10 particles or about 1Ã10 9 -1Ã10 12 particles), or even at least about 1Ã10 10 particles (e.g., about 1Ã10 10 -1Ã10 12 particles) of the adenoviral vector. Alternatively, the dose comprises no more than about 1Ã10 14 particles, preferably no more than about 1Ã10 13 particles, even more preferably no more than about 1Ã10 12 particles, even more preferably no more than about 1Ã10 11 particles, and most preferably no more than about 1Ã10 10 particles (e.g., no more than about 1Ã10 9 articles). Thus, the dose may contain a single dose of adenoviral vector with, for example, about 1Ã10 6 particle units (pu), about 2Ã10 6 pu, about 4Ã10 6 pu, about 1Ã10 7 pu, about 2Ã10 7 pu, about 4Ã10 7 pu, about 1Ã10 8 pu, about 2Ã10 8 pu, about 4Ã10 8 pu, about 1Ã10 9 pu, about 2Ã10 9 pu, about 4Ã10 9 pu, about 1Ã10 10 pu, about 2Ã10 10 pu, about 4Ã10 10 pu, about 1Ã10 11 pu, about 2Ã10 11 pu, about 4Ã10 11 pu, about 1Ã10 12 pu, about 2Ã10 12 pu, or about 4Ã10 12 pu of adenoviral vector. See, for example, the adenoviral vectors in U.S. Pat. No. 8,454,972 B2 to Nabel, et. al., granted on Jun. 4, 2013; incorporated by reference herein, and the dosages at col 29, lines 36-58 thereof. In an embodiment herein, the adenovirus is delivered via multiple doses.

In an embodiment herein, the delivery is via an AAV. A therapeutically effective dosage for in vivo delivery of the AAV to a human is believed to be in the range of from about 20 to about 50 ml of saline solution containing from about 1Ã10 10 to about 1Ã10 10 functional AAV/ml solution. The dosage may be adjusted to balance the therapeutic benefit against any side effects. In an embodiment herein, the AAV dose is generally in the range of concentrations of from about 1Ã10 5 to 1Ã10 50 genomes AAV, from about 1Ã10 8 to 1Ã10 20 genomes AAV, from about 1Ã10 10 to about 1Ã10 16 genomes, or about 1Ã10 11 to about 1Ã10 16 genomes AAV. A human dosage may be about 1Ã10 13 genomes AAV. Such concentrations may be delivered in from about 0.001 ml to about 100 ml, about 0.05 to about 50 ml, or about 10 to about 25 ml of a carrier solution. Other effective dosages can be readily established by one of ordinary skill in the art through routine trials establishing dose response curves. See, for example, U.S. Pat. No. 8,404,658 B2 to Hajjar, et al., granted on Mar. 26, 2013, at col. 27, lines 45-60.

In an embodiment herein the delivery is via a plasmid. In such plasmid compositions, the dosage should be a sufficient amount of plasmid to elicit a response. For instance, suitable quantities of plasmid DNA in plasmid compositions can be from about 0.1 to about 2 mg, or from about 1 Î¼g to about 10 Î¼g.

The doses herein are based on an average 70 kg individual. The frequency of administration is within the ambit of the medical or veterinary practitioner (e.g., physician, veterinarian), or scientist skilled in the art.

The viral vectors can be injected into the tissue of interest. For cell-type specific genome modification, the expression of Cas9 can be driven by a cell-type specific promoter. For example, liver-specific expression might use the Albumin promoter and neuron-specific expression might use the Synapsin I promoter.

RNA delivery: The CRISPR enzyme, for instance a Cas9, and/or any of the present RNAs, for instance a guide RNA, can also be delivered in the form of RNA. Cas9 mRNA can be generated using in vitro transcription. For example, Cas9 mRNA can be synthesized using a PCR cassette containing the following elements: T7_promoter-kozak sequence (GCCACC)-Cas9-3â² UTR from beta globin-polyA tail (a string of 120 or more adenines). The cassette can be used for transcription by T7 polymerase. Guide RNAs can also be transcribed using in vitro transcription from a cassette containing T7_promoter-GG-guide RNA sequence.

To enhance expression and reduce toxicity, the CRISPR enzyme and/or guide RNA can be modified using pseudo-U or 5-Methyl-C.

CRISPR enzyme mRNA and guide RNA may be delivered simultaneously using nanoparticles or lipid envelopes.

For example, Su X, Fricke J, Kavanagh D G, Irvine D J (âIn vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticlesâ Mol Pharm. 2011 Jun. 6; 8 (3): 774-87. doi: 10.1021/mp100390w. Epub 2011 Apr. 1) describes biodegradable core-shell structured nanoparticles with a poly(Î²-amino ester) (PBAE) core enveloped by a phospholipid bilayer shell. These were developed for in vivo mRNA delivery. The pH-responsive PBAE component was chosen to promote endosome disruption, while the lipid surface layer was selected to minimize toxicity of the polycation core. Such are, therefore, preferred for delivering RNA of the present invention.

Furthermore, Michael S D Kormann et al. (âExpression of therapeutic proteins after delivery of chemically modified mRNA in mice: Nature Biotechnology, Volume: 29, Pages: 154-157 (2011) Published online 9 Jan. 2011) describes the use of lipid envelopes to deliver RNA. Use of lipid envelopes is also preferred in the present invention.

mRNA delivery methods are especially promising for liver delivery currently.

CRISPR enzyme mRNA and guideRNA might also be delivered separately. CRISPR enzyme mRNA can be delivered prior to the guide RNA to give time for CRISPR enzyme to be expressed. CRISPR enzyme mRNA might be administered 1-12 hours (preferably around 2-6 hours) prior to the administration of guideRNA.

Alternatively, CRISPR enzyme mRNA and guide RNA can be administered together. Advantageously, a second booster dose of guide RNA can be administered 1-12 hours (preferably around 2-6 hours) after the initial administration of CRISPR enzyme mRNA+guideRNA.

Additional administrations of CRISPR enzyme mRNA and/or guide RNA might be useful to achieve the most efficient levels of genome modification.

For minimization of toxicity and off-target effects, it will be important to control the concentration of CRISPR enzyme mRNA and guide RNA delivered. Optimal concentrations of CRISPR enzyme mRNA and guide RNA can be determined by testing different concentrations in a cellular or animal model and using deep sequencing to analyze the extent of modification at potential off-target genomic loci. For example, for the guide sequence targeting 5â²-GAGTCCGAGCAGAAGAAGAA-3â² (SEQ ID NO: 1) in the EMX1 gene of the human genome, deep sequencing can be used to assess the level of modification at the following two off-target loci, 1: 5â²-GAGTCCTAGCAGGAGAAGAA-3â² (SEQ ID NO: 2) and 2: 5â²-GAGTCTAAGCAGAAGAAGAA-3â² (SEQ ID NO: 3). The concentration that gives the highest level of on-target modification while minimizing the level of off-target modification should be chosen for in vivo delivery.

Alternatively, to minimize the level of toxicity and off-target effects, CRISPR enzyme nickase mRNA (for example S. pyogenes Cas9 with the D10A mutation) can be delivered with a pair of guide RNAs targeting a site of interest. The two guide RNAs need to be spaced as follows. Guide sequences in red (single underline) and blue (double underline) respectively (these examples are based on the PAM requirement for Streptococcus pyogenes Cas9).

Overhang

lengthâ(bp)

GuideâRNAâdesignâ(guideâsequenceâandâPAMâcolorâcoded)

</a

CLAIMS

Claims ( 1 )

What is claimed is:

1 . (A) A non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising

I. a first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, (b) a tracr mate sequence, and (c) a tracr sequence, and II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences, wherein (a), (b) and (c) are arranged in a 5â² to 3â² orientation, wherein components I and II are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, or

(B) a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising

I. a first regulatory element operably linked to (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, and (b) at least one or more tracr mate sequences, II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme, and III. a third regulatory element operably linked to a tracr sequence, wherein components I, II and III are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, and wherein the CRISPR enzyme is a Cas9 ortholog of a genus belonging to the group consisting of Corynebacter, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma and Campylobacter.

US19/025,663

2012-12-12

2025-01-16

Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation

Pending

US20250236856A1

( en )

Priority Applications (1)

Application Number

Priority Date

Filing Date

Title

US19/025,663

US20250236856A1

( en )

2012-12-12

2025-01-16

Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation

Applications Claiming Priority (15)

Application Number

Priority Date

Filing Date

Title

US201261736527P

2012-12-12

US201361748427P

2013-01-02

US201361758468P

2013-01-30

US201361769046P

2013-02-25

US201361802174P

2013-03-15

US201361791409P

2013-03-15

US201361806375P

2013-03-28

US201361814263P

2013-04-20

US201361819803P

2013-05-06

US201361828130P

2013-05-28

US201361836101P

2013-06-17

US201361835931P

2013-06-17

US14/104,977

US20140186919A1

( en )

2012-12-12

2013-12-12

Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation

US15/330,876

US20170198269A1

( en )

2012-12-12

2016-11-07

Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation

US19/025,663

US20250236856A1

( en )

2012-12-12

2025-01-16

Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation

Related Parent Applications (1)

Application Number

Title

Priority Date

Filing Date

US15/330,876

Continuation

US20170198269A1

( en )

2012-12-12

2016-11-07

Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation

Publications (1)

Publication Number

Publication Date

US20250236856A1

true

US20250236856A1 ( en )

2025-07-24

Family

ID=49883291

Family Applications (6)

Application Number

Title

Priority Date

Filing Date

US14/104,977

Abandoned

US20140186919A1

( en )

2012-12-12

2013-12-12

Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation

US14/222,930

Active

US8865406B2

( en )

2012-12-12

2014-03-24

Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation

US14/293,498

Active

US8895308B1

( en )

2012-12-12

2014-06-02

Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation

US14/293,674

Active

US8889418B2

( en )

2012-12-12

2014-06-02

Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation

US15/330,876

Pending

US20170198269A1

( en )

2012-12-12

2016-11-07

Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation

US19/025,663

Pending

US20250236856A1

( en )

2012-12-12

2025-01-16

Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation

Family Applications Before (5)

Application Number

Title

Priority Date

Filing Date

US14/104,977

Abandoned

US20140186919A1

( en )

2012-12-12

2013-12-12

Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation

US14/222,930

Active

US8865406B2

( en )

2012-12-12

2014-03-24

Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation

US14/293,498

Active

US8895308B1

( en )

2012-12-12

2014-06-02

Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation

US14/293,674

Active

US8889418B2

( en )

2012-12-12

2014-06-02

Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation

US15/330,876

Pending

US20170198269A1

( en )

2012-12-12

2016-11-07

Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation

Country Status (15)

Country

Link

( 6 )

US20140186919A1

( en )

( 1 )

EP2898075B1

( en )

( 6 )

JP6552965B2

( en )

( 1 )

KR20150105634A

( en )

( 2 )

CN113355357B

( en )

( 4 )

AU2013359212B2

( en )

( 1 )

CA2894684A1

( en )

( 2 )

DK3064585T3

( en )

( 2 )

ES2576126T3

( en )

( 2 )

IL300461A

( en )

( 1 )

PL2898075T3

( en )

( 1 )

PT2898075E

( en )

( 3 )

SG10201801969TA

( en )

( 1 )

WO2014093635A1

( en )

( 1 )

ZA201504081B

( en )

Families Citing this family (757)

* Cited by examiner, â Cited by third party

Publication number

Priority date

Publication date

Assignee

Title

EP2449112A1

( en )

2009-07-01

2012-05-09

Transposagen Biopharmaceuticals, Inc.

Genetically modified rat models for severe combined immunodeficiency (scid)

EP2689019A2

( en )

2011-03-23

2014-01-29

Pioneer Hi-Bred International Inc.

Methods for producing a complex transgenic trait locus

WO2013066438A2

( en )

2011-07-22

2013-05-10

President And Fellows Of Harvard College

Evaluation and improvement of nuclease cleavage specificity

GB201117313D0

( en )

2011-10-07

2011-11-16

Gt Biolog Ltd

Bacterium for use in medicine

GB201122458D0

( en )

2011-12-30

2012-02-08

Univ Wageningen

Modified cascade ribonucleoproteins and uses thereof

US10039777B2

( en )

2012-03-20

2018-08-07

Neuro-Lm Sas

Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders

RU2645475C2

( en )

2012-04-25

2018-02-21

Ð ÐµÐ³ÐµÐ½ÐµÑÐ¾Ð½ Ð¤Ð°ÑÐ¼Ð°ÑÑÑÑÐ¸ÐºÐ°Ð»Ð·, ÐÐ½Ðº.

Nuclease-mediated targeting with large targeting vectors

LT3401400T

( en )

2012-05-25

2019-06-10

The Regents Of The University Of California

Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription

US10648001B2

( en )

2012-07-11

2020-05-12

Sangamo Therapeutics, Inc.

Method of treating mucopolysaccharidosis type I or II

CA2875618C

( en )

2012-07-11

2021-04-27

Sangamo Biosciences, Inc.

Methods and compositions for the treatment of lysosomal storage diseases

JP2015527889A

( en )

2012-07-25

2015-09-24

ã¶ ããã¼ã ã¤ã³ã¹ãã£ãã¥ã¼ãï¼ ã¤ã³ã³ã¼ãã¬ã¤ããã

Inducible DNA binding protein and genomic disruption tools and their applications

PL4397760T3

( en )

2012-10-23

2026-03-30

Toolgen Incorporated

A COMPOSITION FOR CLEFULNING A TARGET DNA COMPRISING A GUIDE RNA SPECIFIC FOR A TARGET DNA AND A NUCLEIC ACID ENCODING A CAS PROTEIN OR A CAS PROTEIN, AND USE THEREOF

EP3135765A1

( en )

2012-12-06

2017-03-01

Sigma-Aldrich Co. LLC

Crispr-based genome modification and regulation

EP3434776A1

( en )

2012-12-12

2019-01-30

The Broad Institute, Inc.

Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof

US8697359B1

( en )

2012-12-12

2014-04-15

The Broad Institute, Inc.

CRISPR-Cas systems and methods for altering expression of gene products

WO2014093701A1

( en )

2012-12-12

2014-06-19

The Broad Institute, Inc.

Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof

IL239317B

( en )

2012-12-12

2022-07-01

Broad Inst Inc

Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications

CN114634950A

( en )

2012-12-12

2022-06-17

å¸ç½å¾·ç ç©¶ææéå¬å¸

CRISPR-CAS component systems, methods, and compositions for sequence manipulation

EP2931898B1

( en )

2012-12-12

2016-03-09

The Broad Institute, Inc.

Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains

EP2896697B1

( en )

2012-12-12

2015-09-02

The Broad Institute, Inc.

Engineering of systems, methods and optimized guide compositions for sequence manipulation

ES2576126T3

( en )

2012-12-12

2016-07-05

The Broad Institute, Inc.

Modification by genetic technology and optimization of improved enzyme systems, methods and compositions for sequence manipulation

SG10201912991WA

( en )

2012-12-17

2020-03-30

Harvard College

Rna-guided human genome engineering

EP3919505B1

( en )

2013-01-16

2023-08-30

Emory University

Uses of cas9-nucleic acid complexes

US20140235933A1

( en )

2013-02-20

2014-08-21

Regeneron Pharmaceuticals, Inc.

Genetic modification of rats

SG11201507378UA

( en )

2013-03-14

2015-10-29

Caribou Biosciences Inc

Compositions and methods of nucleic acid-targeting nucleic acids

US10760064B2

( en )

2013-03-15

2020-09-01

The General Hospital Corporation

RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci

US9234213B2

( en )

2013-03-15

2016-01-12

System Biosciences, Llc

Compositions and methods directed to CRISPR/Cas genomic engineering systems

WO2014204578A1

( en )

2013-06-21

2014-12-24

The General Hospital Corporation

Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing

US10378027B2

( en )

2013-03-15

2019-08-13

The General Hospital Corporation

RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci

JP2016522679A

( en )

2013-04-04

2016-08-04

ãã¬ã¸ãã³ã ã¢ã³ã ãã§ãã¼ãº ãªã ãã¼ãã¼ã ã«ã¬ãã¸

Therapeutic use of genome editing with the CRISPR / Cas system

GB201306536D0

( en )

2013-04-10

2013-05-22

Gt Biolog Ltd

Polypeptide and immune modulation

WO2014172470A2

( en )

2013-04-16

2014-10-23

Whitehead Institute For Biomedical Research

Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal

DK2986729T3

( en )

2013-04-16

2018-10-29

Regeneron Pharma

TARGETED MODIFICATION OF ROOT THROUGH

WO2014186686A2

( en )

2013-05-17

2014-11-20

Two Blades Foundation

Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases

EP3004339B1

( en )

2013-05-29

2021-07-07

Cellectis

New compact scaffold of cas9 in the type ii crispr system

WO2014194190A1

( en )

2013-05-30

2014-12-04

The Penn State Research Foundation

Gene targeting and genetic modification of plants via rna-guided genome editing

JP6665088B2

( en )

2013-06-17

2020-03-13

ã¶ã»ããã¼ãã»ã¤ã³ã¹ãã£ãã¥ã¼ãã»ã¤ã³ã³ã¼ãã¬ã¤ããã

Optimized CRISPR-Cas double nickase system, method and composition for sequence manipulation

WO2014204724A1

( en )

2013-06-17

2014-12-24

The Broad Institute Inc.

Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation

MX2015017312A

( en )

2013-06-17

2017-04-10

Broad Inst Inc

SUPPLY AND USE OF CRISPR-CAS COMPOSITIONS, VECTORS AND SYSTEMS FOR DIRECTED MODIFICATION AND HEPATIC THERAPY.

EP3725885A1

( en )

2013-06-17

2020-10-21

The Broad Institute, Inc.

Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof

CN105793425B

( en )

2013-06-17

2021-10-26

å¸ç½å¾·ç ç©¶ææéå¬å¸

Delivery, use and therapeutic applications of CRISPR-CAS systems and compositions for targeting disorders and diseases using viral components

JP2016528890A

( en )

2013-07-09

2016-09-23

ãã¬ã¸ãã³ã ã¢ã³ã ãã§ãã¼ãº ãªã ãã¼ãã¼ã ã«ã¬ãã¸

Therapeutic use of genome editing using the CRISPR / Cas system

BR112016000571B1

( en )

2013-07-10

2023-12-26

President And Fellows Of Harvard College

IN VITRO METHODS FOR MODULATING EXPRESSION AND FOR ALTERING ONE OR MORE TARGET NUCLEIC ACIDS IN A CELL SIMULTANEOUSLY WITH REGULATING THE EXPRESSION OF ONE OR MORE TARGET NUCLEIC ACIDS IN A CELL AS WELL AS A YEAST OR BACTERIAL CELL COMPRISING NUCLEIC ACIDS

US10563225B2

( en )

2013-07-26

2020-02-18

President And Fellows Of Harvard College

Genome engineering

US20150044192A1

( en )

2013-08-09

2015-02-12

President And Fellows Of Harvard College

Methods for identifying a target site of a cas9 nuclease

CA3221516A1

( en )

2013-08-22

2015-02-26

E. I. Du Pont De Nemours And Company

Plant genome modification using guide rna/cas endonuclease systems and methods of use

US9359599B2

( en )

2013-08-22

2016-06-07

President And Fellows Of Harvard College

Engineered transcription activator-like effector (TALE) domains and uses thereof

CA2922428A1

( en )

2013-08-29

2015-03-05

Temple University Of The Commonwealth System Of Higher Education

Methods and compositions for rna-guided treatment of hiv infection

US9526784B2

( en )

2013-09-06

2016-12-27

President And Fellows Of Harvard College

Delivery system for functional nucleases

US9388430B2

( en )

2013-09-06

2016-07-12

President And Fellows Of Harvard College

Cas9-recombinase fusion proteins and uses thereof

US9340799B2

( en )

2013-09-06

2016-05-17

President And Fellows Of Harvard College

MRNA-sensing switchable gRNAs

ES2844174T3

( en )

2013-09-18

2021-07-21

Kymab Ltd

Methods, cells and organisms

WO2015054507A1

( en )

2013-10-10

2015-04-16

Pronutria, Inc.

Nutritive polypeptide production systems, and methods of manufacture and use thereof

WO2015065964A1

( en )

2013-10-28

2015-05-07

The Broad Institute Inc.

Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof

CN106459995B

( en )

2013-11-07

2020-02-21

ç±è¿ªå¡æ¯å»è¯æéå¬å¸

CRISPR-related methods and compositions using dominant gRNAs

CA2930877A1

( en )

2013-11-18

2015-05-21

Crispr Therapeutics Ag

Crispr-cas system materials and methods

US9074199B1

( en )

2013-11-19

2015-07-07

President And Fellows Of Harvard College

Mutant Cas9 proteins

WO2015088643A1

( en )

2013-12-11

2015-06-18

Regeneron Pharmaceuticals, Inc.

Methods and compositions for the targeted modification of a genome

BR112016013547A2

( en )

2013-12-12

2017-10-03

Broad Inst Inc

COMPOSITIONS AND METHODS OF USE OF CRISPR-CAS SYSTEMS IN NUCLEOTIDE REPEAT DISORDERS

CN111206032B

( en )

2013-12-12

2024-07-19

Delivery, use and therapeutic applications of CRISPR-CAS systems and compositions for genome editing

WO2015089473A1

( en )

2013-12-12

2015-06-18

The Broad Institute Inc.

Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation

WO2015089486A2

( en )

2013-12-12

2015-06-18

The Broad Institute Inc.

Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems

WO2015089427A1

( en )

2013-12-12

2015-06-18

The Broad Institute Inc.

Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes

BR112016013213A2

( en )

2013-12-12

2017-12-05

Massachusetts Inst Technology

administration, use and therapeutic applications of crisper systems and compositions for targeting disorders and diseases using particle delivery components

WO2015089364A1

( en )

2013-12-12

2015-06-18

The Broad Institute Inc.

Crystal structure of a crispr-cas system, and uses thereof

RU2016128077A

( en )

2013-12-12

2018-12-06

Ð¢Ðµ ÐÑÐ¾Ð´ ÐÐ½ÑÑÐ¸ÑÑÑÑ ÐÐ½Ðº.

DELIVERY, APPLICATION AND APPLICATIONS IN THE THERAPY OF CRISPR-CAS SYSTEMS AND COMPOSITIONS FOR TREATMENT OF CONDITIONED HBV AND VIRAL DISEASES AND DISORDERS

US20150166984A1

( en )

2013-12-12

2015-06-18

President And Fellows Of Harvard College

Methods for correcting alpha-antitrypsin point mutations

CA2931684C

( en )

2013-12-19

2024-02-20

Novartis Ag

Human mesothelin chimeric antigen receptors and uses thereof

EP4063503A1

( en )

2014-02-11

2022-09-28

The Regents of the University of Colorado, a body corporate

Crispr enabled multiplexed genome engineering

EP3107999A4

( en )

2014-02-18

2017-10-04

Duke University

Compositions for the inactivation of virus replication and methods of making and using the same

EP3971283A1

( en )

2014-02-27

2022-03-23

Monsanto Technology LLC

Compositions and methods for site directed genomic modification

WO2015130968A2

( en )

2014-02-27

2015-09-03

The Broad Institute Inc.

T cell balance gene expression, compositions of matters and methods of use thereof

US11028388B2

( en )

2014-03-05

2021-06-08

Editas Medicine, Inc.

CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa

CA2948728A1

( en )

2014-03-10

2015-09-17

Editas Medicine, Inc.

Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)

US11141493B2

( en )

2014-03-10

2021-10-12

Editas Medicine, Inc.

Compositions and methods for treating CEP290-associated disease

US11339437B2

( en )

2014-03-10

2022-05-24

Editas Medicine, Inc.

Compositions and methods for treating CEP290-associated disease

EP3593812A3

( en )

2014-03-15

2020-05-27

Novartis AG

Treatment of cancer using chimeric antigen receptor

WO2015148863A2

( en )

2014-03-26

2015-10-01

Editas Medicine, Inc.

Crispr/cas-related methods and compositions for treating sickle cell disease

EP3498845B1

( en )

2014-04-01

2022-06-22

Editas Medicine, Inc.

Crispr/cas-related methods and compositions for treating herpes simplex virus type 1 (hsv-1)

EP3126495A1

( en )

2014-04-02

2017-02-08

Editas Medicine, Inc.

Crispr/cas-related methods and compositions for treating primary open angle glaucoma

IL322264A

( en )

2014-04-07

2025-09-01

Novartis Ag

Treatment of cancer using anti-cd19 chimeric antigen receptor

WO2015157070A2

( en )

2014-04-09

2015-10-15

Editas Medicine, Inc.

Crispr/cas-related methods and compositions for treating cystic fibrosis

KR102595473B1

( en )

2014-04-18

2023-10-30

Crispr-cas-related methods, compositions and components for cancer immunotherapy

KR20170005494A

( en )

2014-05-30

2017-01-13

Compositions and methods of delivering treatments for latent viral infections

RU2704283C9

( en )

2014-06-06

2020-02-07

Ð ÐµÐ³ÐµÐ½ÐµÑÐ¾Ð½ Ð¤Ð°ÑÐ¼Ð°ÑÑÑÑÐ¸ÐºÐ°Ð»Ð·, ÐÐ½Ðº.

Methods and compositions for modifying target locus

EP3154694B1

( en )

2014-06-13

2025-01-29

Children's Medical Center Corporation

Products and methods to isolate mitochondria

EP3919621A1

( en )

2014-06-23

2021-12-08

The General Hospital Corporation

Genomewide unbiased identification of dsbs evaluated by sequencing (guide-seq)

PT3161128T

( en )

2014-06-26

2018-11-21

Regeneron Pharma

Methods and compositions for targeted genetic modifications and methods of use

CN106687594A

( en )

2014-07-11

2017-05-17

çº³å¹å°æé¦å¬å¸

Compositions and methods for producing plants resistant to glyphosate herbicide

FI3169778T3

( en )

2014-07-14

2023-12-13

Univ Washington State

Nanos knock-out that ablates germline cells

CN104152414B

( en )

2014-07-18

2018-03-13

The method that genetic modification is carried out to the predetermined site of cellular genome

US11542488B2

( en )

2014-07-21

2023-01-03

Novartis Ag

Sortase synthesized chimeric antigen receptors

WO2016014530A1

( en )

2014-07-21

2016-01-28

Novartis Ag

Combinations of low, immune enhancing. doses of mtor inhibitors and cars

US9777061B2

( en )

2014-07-21

2017-10-03

Novartis Ag

Treatment of cancer using a CD33 chimeric antigen receptor

MY181834A

( en )

2014-07-21

2021-01-08

Novartis Ag

Treatment of cancer using humanized anti-bcma chimeric antigen receptor

WO2016022363A2

( en )

2014-07-30

2016-02-11

President And Fellows Of Harvard College

Cas9 proteins including ligand-dependent inteins

US20170209492A1

( en )

2014-07-31

2017-07-27

Novartis Ag

Subset-optimized chimeric antigen receptor-containing t-cells

WO2016021973A1

( en )

2014-08-06

2016-02-11

ì£¼ìíì¬ í´ì

Genome editing using campylobacter jejuni crispr/cas system-derived rgen

CN106714845A

( en )

2014-08-11

2017-05-24

å¾åè¨æ¯å·å¤§å¦ç³»ç»è£äºä¼

Prevention of muscular dystrophy by crispr/cas9-mediated gene editing

WO2016025880A1

( en )

2014-08-14

2016-02-18

Novartis Ag

Treatment of cancer using gfr alpha-4 chimeric antigen receptor

DK3180426T3

( en )

2014-08-17

2020-03-30

Broad Inst Inc

RETURNING BY USING CAS9 NICKASES

SG11201700770PA

( en )

2014-08-19

2017-03-30

Novartis Ag

Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment

CA2959070C

( en )

2014-08-27

2020-11-10

Caribou Biosciences, Inc.

Methods for increasing cas9-mediated engineering efficiency

US10570418B2

( en )

2014-09-02

2020-02-25

The Regents Of The University Of California

Methods and compositions for RNA-directed target DNA modification

BR112017003757A2

( en )

2014-09-12

2017-12-26

Du Pont

? corn plants, parts of corn plants or corn seeds?

ES2891332T3

( en )

2014-09-17

2022-01-27

Novartis Ag

Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy

WO2016049024A2

( en )

2014-09-24

2016-03-31

The Broad Institute Inc.

Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo

WO2016049163A2

( en )

2014-09-24

2016-03-31

The Broad Institute Inc.

Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder

Engineering and optimization of improved systems, methods and enzyme … — The Broad Institute, Inc. (US20250236856A1)

Related documents